Pathogenetic processes

Pathogenetic processes (PPs) — are major molecular and phenotypic characteristics that determinate cancer as complex evolutionary disease process.


Name ( total associations | neutral | plus | minus )


Invasion ( 3167 / 1609 /
507
/
1051
)
migration ( 2549 / 1290 /
407
/
852
)
colony formation ( 425 / 218 /
55
/
152
)
cell cycle ( 250 / 131 /
44
/
75
)
Proliferation ( 3558 / 1799 /
566
/
1193
)
cell cycle progression ( 171 / 87 /
42
/
42
)
Cell growth ( 726 / 367 /
105
/
254
)
Senescence ( 65 / 36 /
21
/
8
)
cell cycle arrest ( 501 / 254 /
219
/
28
)
MTX resistance ( 3 / 2 /
0
/
1
)
Tomudex (TDX) resistance ( 1 / 1 /
0
/
0
)
Metastasis ( 1007 / 512 /
192
/
303
)
AKT signaling ( 245 / 124 /
42
/
79
)
cisplatin resistance ( 280 / 141 /
43
/
96
)
Autophagy ( 317 / 159 /
73
/
85
)
survival ( 132 / 68 /
23
/
41
)
Apoptosis ( 1602 / 815 /
518
/
269
)
cell viability ( 264 / 136 /
34
/
94
)
5fluorouracil resistance ( 90 / 54 /
15
/
21
)
G1-S checkpoint ( 7 / 4 /
2
/
1
)
Lung metastasis ( 55 / 29 /
11
/
15
)
DNA repair ( 55 / 28 /
19
/
8
)
TGF-beta signaling ( 366 / 206 /
78
/
82
)
motility ( 185 / 95 /
30
/
60
)
EMT ( 745 / 379 /
156
/
210
)
stemness ( 201 / 101 /
46
/
54
)
BMP signaling ( 108 / 63 /
13
/
32
)
Hedgehog (Hh) signaling ( 31 / 16 /
5
/
10
)
JAK/STAT signaling ( 94 / 48 /
24
/
22
)
Angiogenesis ( 270 / 140 /
44
/
86
)
growth ( 222 / 131 /
26
/
65
)
tumor-initiating properties ( 9 / 6 /
0
/
3
)
tumor growth ( 684 / 345 /
114
/
225
)
Chemoresistance ( 264 / 133 /
46
/
85
)
Paclitaxel resistance ( 57 / 29 /
12
/
16
)
beta-catenin signaling ( 49 / 25 /
11
/
13
)
Brain metastasis ( 2 / 1 /
0
/
1
)
docetaxel resistance ( 31 / 17 /
10
/
4
)
cyclophosphamide sensitivity ( 1 / 1 /
0
/
0
)
recurrence ( 2 / 2 /
0
/
0
)
adhesion ( 49 / 27 /
7
/
15
)
NF-kB signaling ( 143 / 73 /
39
/
31
)
Antiapoptosis ( 37 / 20 /
12
/
5
)
Oxaliplatin resistance ( 23 / 12 /
5
/
6
)
Anoikis ( 22 / 12 /
4
/
6
)
MET ( 18 / 10 /
8
/
0
)
differentiation ( 95 / 48 /
31
/
16
)
Tamoxifen resistance ( 19 / 10 /
6
/
3
)
Radioresistance ( 111 / 57 /
22
/
32
)
inflammation ( 67 / 34 /
10
/
23
)
redox homeostasis ( 3 / 3 /
0
/
0
)
Sorafenib resistance ( 28 / 14 /
6
/
8
)
tumor progression ( 82 / 42 /
24
/
16
)
aerobic glycolysis ( 59 / 30 /
10
/
19
)
ER stress ( 28 / 15 /
0
/
13
)
Oxaliplatin ( 2 / 1 /
1
/
0
)
cellular repair of DNA double-strand breaks ( 1 / 1 /
0
/
0
)
etoposide ( 7 / 4 /
2
/
1
)
RAS signaling pathway ( 8 / 5 /
1
/
2
)
doxorubicin resistance ( 65 / 33 /
8
/
24
)
multidrug resistance ( 20 / 11 /
4
/
5
)
ERK pathway (MAPK pathway) ( 131 / 66 /
21
/
44
)
Liver metastasis ( 24 / 14 /
3
/
7
)
scattering ( 1 / 1 /
0
/
0
)
HCPT (Hydroxycamptothecin) resistantance ( 1 / 1 /
0
/
0
)
cell polarity ( 1 / 1 /
0
/
0
)
cell spreading ( 8 / 6 /
0
/
2
)
Temozolomide (TMZ) resistance ( 26 / 13 /
5
/
8
)
WNT signaling ( 212 / 107 /
52
/
53
)
cancer progression ( 16 / 9 /
5
/
2
)
PI3K signaling ( 85 / 43 /
12
/
30
)
inflammatory monocyte recruitment ( 4 / 3 /
0
/
1
)
erythropoiesis ( 3 / 3 /
0
/
0
)
NK cell cytotoxicity ( 6 / 4 /
0
/
2
)
Response to genotoxic stress ( 2 / 2 /
0
/
0
)
mitoxantrone (MX) Resistance ( 1 / 1 /
0
/
0
)
Castrate Resistance ( 25 / 15 /
8
/
2
)
Bone metastasis ( 18 / 11 /
1
/
6
)
anchorage-independent growth ( 29 / 15 /
9
/
5
)
Camptothecin resistance ( 3 / 2 /
0
/
1
)
macrophage attraction ( 1 / 1 /
0
/
0
)
tumor-stroma interactions ( 3 / 2 /
1
/
0
)
Imatinib resistance ( 12 / 8 /
0
/
4
)
myeloid differentiation ( 27 / 14 /
7
/
6
)
microtubule-targeting drugs ( 4 / 4 /
0
/
0
)
disease-free survival ( 3 / 2 /
0
/
1
)
epirubicin resistance ( 5 / 3 /
2
/
0
)
Transformation ( 15 / 12 /
2
/
1
)
neutrophil chemotaxis ( 2 / 2 /
0
/
0
)
NOTCH signaling ( 55 / 28 /
15
/
12
)
gefitinib resistance ( 28 / 15 /
4
/
9
)
Hepatocyte differentation ( 2 / 2 /
0
/
0
)
poor prognosis ( 46 / 26 /
17
/
3
)
unfolded protein response ( 5 / 4 /
0
/
1
)
P38 signaling ( 29 / 15 /
10
/
4
)
Vorinostat Resistance ( 6 / 4 /
2
/
0
)
Osteolysis ( 5 / 3 /
0
/
2
)
EGFR-TKI resistance ( 2 / 2 /
0
/
0
)
Tumorigenesis ( 43 / 22 /
7
/
14
)
Adriamycin (Adr) resistance ( 26 / 14 /
3
/
9
)
lipogenesis ( 23 / 12 /
0
/
11
)
mTOR signaling ( 76 / 38 /
8
/
30
)
cytotoxicity ( 2 / 1 /
1
/
0
)
gluconeogenesis ( 4 / 2 /
0
/
2
)
chondrogenesis ( 1 / 1 /
0
/
0
)
Lapatinib resistance ( 2 / 1 /
0
/
1
)
Neratinib resistance ( 2 / 1 /
0
/
1
)
Afatinib resistance ( 2 / 1 /
0
/
1
)
daunorubicin (DNR) Resistance ( 4 / 2 /
2
/
0
)
Response to oxidative stress ( 5 / 5 /
0
/
0
)
T cell activation ( 3 / 2 /
1
/
0
)
gemcitabine resistance ( 42 / 21 /
7
/
14
)
genomic instability ( 2 / 1 /
1
/
0
)
glycolysis ( 11 / 11 /
0
/
0
)
insulin signaling ( 1 / 1 /
0
/
0
)
endothelial-mesenchymal transition ( 1 / 1 /
0
/
0
)
branching-morphogenesis ( 1 / 1 /
0
/
0
)
Taxanes (paclitaxel and docetaxel) resistance ( 8 / 7 /
0
/
1
)
Vinblastine (Velban) resistance ( 1 / 1 /
0
/
0
)
Hippo signaling pathway ( 164 / 82 /
65
/
17
)
glucose metabolism ( 18 / 9 /
3
/
6
)
BRCAness ( 2 / 1 /
1
/
0
)
BRAFi resistance ( 4 / 2 /
1
/
1
)
MEKi resistance ( 4 / 2 /
1
/
1
)
immunoevasion ( 16 / 8 /
3
/
5
)
MAPK/JNK Signaling Pathway ( 10 / 5 /
5
/
0
)
Hypoxic response ( 8 / 5 /
3
/
0
)
carboplatin resistance ( 2 / 1 /
0
/
1
)
Trastuzumab resistance ( 6 / 3 /
1
/
2
)
fibrosis ( 28 / 14 /
6
/
8
)
TRAIL resistance ( 2 / 1 /
0
/
1
)
Rapamycin resistance ( 2 / 1 /
0
/
1
)
Cetuximab resistance ( 20 / 10 /
7
/
3
)
BCL2 inhibitors resistance ( 2 / 1 /
0
/
1
)
Necrosis ( 4 / 2 /
1
/
1
)
pyroptosis ( 2 / 1 /
1
/
0
)